Transformation of primary human hepatocytes in hepatocellular carcinoma

Montalbano,Mauro; Rastellini,Cristiana; Wang,Xiaofu; Corsello,Tiziana; Eltorky,Mahmoud A.; Vento,Renza; Cicalese,Luca

doi:10.3892/ijo.2015.3312

Transformation of primary human hepatocytes in hepatocellular carcinoma

Authors:
- Mauro Montalbano
- Cristiana Rastellini
- Xiaofu Wang
- Tiziana Corsello
- Mahmoud A. Eltorky
- Renza Vento
- Luca Cicalese
View Affiliations

Affiliations: Department of Surgery, University of Texas Medical Branch, Galveston, TX, USA, Department of Pathology, University of Texas Medical Branch, Galveston, TX, USA, Laboratory of Biochemistry, Department of Biological, Chemical and Pharmaceutical Sciences and Technologies, Polyclinic, University of Palermo, Palermo, Italy
Published online on: December 28, 2015 https://doi.org/10.3892/ijo.2015.3312
Pages: 1205-1217

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Hepatocellular carcinoma (HCC) is the most common primary liver cancer. Currently, there is limited knowledge of neoplastic transformation of hepatocytes in HCC. In clinical practice, the high rate of HCC local recurrence suggests the presence of different hepatocyte populations within the liver and particularly in the tumor proximity. The present study investigated primary human hepatocyte cultures obtained from liver specimens of patients affected by cirrhosis and HCC, their proliferation and transformation. Liver samples were obtained from seven HCC cirrhotic patients and from three patients with normal liver (NL). Immediately after surgery, cell outgrowth and primary cultures were obtained from the HCC lesion, the cirrhotic tissue proximal (CP, 1-3 cm) and distal (CD, >5 cm) to the margin of the neoplastic lesion, or from NL. Cells were kept in culture for 16 weeks. Morphologic analyses were performed and proliferation rate of the different cell populations compared over time. Glypican-3, Heppar1, Arginase1 and CD-44 positivity were tested. The degree of invasiveness of cells acquiring neoplastic characteristics was studied with a transwell migration assay. We observed that HCC cells maintained their morphology and unmodified neoplastic characteristics when cultured. Cells isolated from CP, showed a progressive morphologic transformation in HCC-like cells accompanied by modification of markers expression with signs of invasiveness. Absence of HCC contamination in the CP isolates was confirmed. In CD samples some of these characteristics were present and at significantly lower levels. With the present study, we are the first to have identified and describe the existence of human hepatocytes near the cancerous lesion that can transform in HCC in vitro.

View Figures

View References

1	El-Serag HB: Hepatocellular carcinoma: Recent trends in the United States. Gastroenterology. 127(Suppl 1): S27–S34. 2004. View Article : Google Scholar : PubMed/NCBI
2	El-Serag HB: Epidemiology of viral hepatitis and hepatocellular carcinoma. Gastroenterology. 142:1264–1273.e1. 2012. View Article : Google Scholar : PubMed/NCBI
3	Mittal S and El-Serag HB: Epidemiology of hepatocellular carcinoma: Consider the population. J Clin Gastroenterol. 47(Suppl): S2–S6. 2013. View Article : Google Scholar : PubMed/NCBI
4	Poon RT, Ng IO, Fan ST, Lai EC, Lo CM, Liu CL and Wong J: Clinicopathologic features of long-term survivors and disease-free survivors after resection of hepatocellular carcinoma: A study of a prospective cohort. J Clin Oncol. 19:3037–3044. 2001.PubMed/NCBI
5	Roayaie S, Obeidat K, Sposito C, Mariani L, Bhoori S, Pellegrinelli A, Labow D, Llovet JM, Schwartz M and Mazzaferro V: Resection of hepatocellular cancer ≤2 cm: Results from two Western centers. Hepatology. 57:1426–1435. 2013. View Article : Google Scholar
6	Earl TM and Chapman WC: Hepatocellular carcinoma: Resection versus transplantation. Semin Liver Dis. 33:282–292. 2013. View Article : Google Scholar : PubMed/NCBI
7	Peng ZW, Lin XJ, Zhang YJ, Liang HH, Guo RP, Shi M and Chen MS: Radiofrequency ablation versus hepatic resection for the treatment of hepatocellular carcinomas 2 cm or smaller: A retrospective comparative study. Radiology. 262:1022–1033. 2012. View Article : Google Scholar : PubMed/NCBI
8	Ramakrishna G, Rastogi A, Trehanpati N, Sen B, Khosla R and Sarin SK: From cirrhosis to hepatocellular carcinoma: New molecular insights on inflammation and cellular senescence. Liver Cancer. 2:367–383. 2013. View Article : Google Scholar
9	Zhao YJ, Ju Q and Li GC: Tumor markers for hepatocellular carcinoma. Mol Clin Oncol. 1:593–598. 2013.
10	Timek DT, Shi J, Liu H and Lin F: Arginase-1, HepPar-1, and Glypican-3 are the most effective panel of markers in distinguishing hepatocellular carcinoma from metastatic tumor on fine-needle aspiration specimens. Am J Clin Pathol. 138:203–210. 2012. View Article : Google Scholar : PubMed/NCBI
11	Tomuleasa C, Soritau O, Rus-Ciuca D, Pop T, Todea D, Mosteanu O, Pintea B, Foris V, Susman S, Kacsó G, et al: Isolation and characterization of hepatic cancer cells with stem-like properties from hepatocellular carcinoma. J Gastrointestin Liver Dis. 19:61–67. 2010.PubMed/NCBI
12	Krings G, Ramachandran R, Jain D, Wu TT, Yeh MM, Torbenson M and Kakar S: Immunohistochemical pitfalls and the importance of glypican 3 and arginase in the diagnosis of scirrhous hepatocellular carcinoma. Mod Pathol. 26:782–791. 2013. View Article : Google Scholar : PubMed/NCBI
13	Shiran MS, Isa MR, Sherina MS, Rampal L, Hairuszah I and Sabariah AR: The utility of hepatocyte paraffin 1 antibody in the immunohistological distinction of hepatocellular carcinoma from cholangiocarcinoma and metastatic carcinoma. Malays J Pathol. 28:87–92. 2006.
14	Pfeiffer E, Kegel V, Zeilinger K, Hengstler JG, Nüssler AK, Seehofer D and Damm G: Featured Article: Isolation, characterization, and cultivation of human hepatocytes and non-parenchymal liver cells. Exp Biol Med (Maywood). 240:645–656. 2015. View Article : Google Scholar
15	Ihara A, Koizumi H, Hashizume R and Uchikoshi T: Expression of epithelial cadherin and alpha- and beta-catenins in nontumoral livers and hepatocellular carcinomas. Hepatology. 23:1441–1447. 1996.PubMed/NCBI
16	Wands JR and Kim M: WNT/β-catenin signaling and hepatocellular carcinoma. Hepatology. 60:452–454. 2014. View Article : Google Scholar : PubMed/NCBI
17	Ho M and Kim H: Glypican-3: A new target for cancer immunotherapy. Eur J Cancer. 47:333–338. 2011. View Article : Google Scholar :
18	The International Consensus Group for Hepatocellular Neoplasia. Pathologic diagnosis of early hepatocellular carcinoma: A report of the international consensus group for hepatocellular neoplasia. Hepatology. 49:658–664. 2009. View Article : Google Scholar : PubMed/NCBI
19	Capurro M, Martin T, Shi W and Filmus J: Glypican-3 binds to Frizzled and plays a direct role in the stimulation of canonical Wnt signaling. J Cell Sci. 127:1565–1575. 2014. View Article : Google Scholar : PubMed/NCBI
20	Capurro MI, Xiang YY, Lobe C and Filmus J: Glypican-3 promotes the growth of hepatocellular carcinoma by stimulating canonical Wnt signaling. Cancer Res. 65:6245–6254. 2005. View Article : Google Scholar : PubMed/NCBI
21	Yao M, Wang L, Dong Z, Qian Q, Shi Y, Yu D, Wang S, Zheng W and Yao D: Glypican-3 as an emerging molecular target for hepatocellular carcinoma gene therapy. Tumour Biol. 35:5857–5868. 2014. View Article : Google Scholar : PubMed/NCBI
22	Zhu Z, Hao X, Yan M, Yao M, Ge C, Gu J and Li J: Cancer stem/progenitor cells are highly enriched in CD133⁺CD44⁺ population in hepatocellular carcinoma. Int J Cancer. 126:2067–2078. 2010. View Article : Google Scholar
23	Endo K and Terada T: Protein expression of CD44 (standard and variant isoforms) in hepatocellular carcinoma: Relationships with tumor grade, clinicopathologic parameters, p53 expression, and patient survival. J Hepatol. 32:78–84. 2000. View Article : Google Scholar : PubMed/NCBI
24	Afify A, Purnell P and Nguyen L: Role of CD44s and CD44v6 on human breast cancer cell adhesion, migration, and invasion. Exp Mol Pathol. 86:95–100. 2009. View Article : Google Scholar : PubMed/NCBI
25	Xie Z, Choong PF, Poon LF, Zhou J, Khng J, Jasinghe VJ, Palaniyandi S and Chen CS: Inhibition of CD44 expression in hepatocellular carcinoma cells enhances apoptosis, chemosensitivity, and reduces tumorigenesis and invasion. Cancer Chemother Pharmacol. 62:949–957. 2008. View Article : Google Scholar : PubMed/NCBI
26	Blaner WS, O'Byrne SM, Wongsiriroj N, Kluwe J, D'Ambrosio DM, Jiang H, Schwabe RF, Hillman EM, Piantedosi R and Libien J: Hepatic stellate cell lipid droplets: A specialized lipid droplet for retinoid storage. Biochim Biophys Acta. 1791:467–473. 2009. View Article : Google Scholar :
27	Amann T, Bataille F, Spruss T, Mühlbauer M, Gäbele E, Schölmerich J, Kiefer P, Bosserhoff AK and Hellerbrand C: Activated hepatic stellate cells promote tumorigenicity of hepatocellular carcinoma. Cancer Sci. 100:646–653. 2009. View Article : Google Scholar : PubMed/NCBI
28	Yu G, Jing Y, Kou X, Ye F, Gao L, Fan Q, Yang Y, Zhao Q, Li R, Wu M, et al: Hepatic stellate cells secreted hepatocyte growth factor contributes to the chemoresistance of hepatocellular carcinoma. PLoS One. 8:e733122013. View Article : Google Scholar : PubMed/NCBI
29	Geng ZM, Li QH, Li WZ, Zheng JB and Shah V: Activated human hepatic stellate cells promote growth of human hepatocellular carcinoma in a subcutaneous xenograft nude mouse model. Cell Biochem Biophys. 70:337–347. 2014. View Article : Google Scholar : PubMed/NCBI
30	Gao D, Vela I, Sboner A, Iaquinta PJ, Karthaus WR, Gopalan A, Dowling C, Wanjala JN, Undvall EA, Arora VK, et al: Organoid cultures derived from patients with advanced prostate cancer. Cell. 159:176–187. 2014. View Article : Google Scholar : PubMed/NCBI
31	Liang Y, Shilagard T, Xiao SY, Snyder N, Lau D, Cicalese L, Weiss H, Vargas G and Lemon SM: Visualizing hepatitis C virus infections in human liver by two-photon microscopy. Gastroenterology. 137:1448–1458. 2009. View Article : Google Scholar : PubMed/NCBI
32	Sachs N and Clevers H: Organoid cultures for the analysis of cancer phenotypes. Curr Opin Genet Dev. 24:68–73. 2014. View Article : Google Scholar : PubMed/NCBI
33	Zittermann SI, Capurro MI, Shi W and Filmus J: Soluble glypican 3 inhibits the growth of hepatocellular carcinoma in vitro and in vivo. Int J Cancer. 126:1291–1301. 2010.
34	Sun CK, Chua MS, He J and So SK: Suppression of glypican 3 inhibits growth of hepatocellular carcinoma cells through up-regulation of TGF-β2. Neoplasia. 13:735–747. 2011. View Article : Google Scholar : PubMed/NCBI
35	Gao W, Kim H, Feng M, Phung Y, Xavier CP, Rubin JS and Ho M: Inactivation of Wnt signaling by a human antibody that recognizes the heparan sulfate chains of glypican-3 for liver cancer therapy. Hepatology. 60:576–587. 2014. View Article : Google Scholar : PubMed/NCBI
36	Liu S, Li Y, Chen W, Zheng P, Liu T, He W, Zhang J and Zeng X: Silencing glypican-3 expression induces apoptosis in human hepatocellular carcinoma cells. Biochem Biophys Res Commun. 419:656–661. 2012. View Article : Google Scholar : PubMed/NCBI
37	Stock P, Brückner S, Ebensing S, Hempel M, Dollinger MM and Christ B: The generation of hepatocytes from mesenchymal stem cells and engraftment into murine liver. Nat Protoc. 5:617–627. 2010. View Article : Google Scholar : PubMed/NCBI